InsidersTradesSigma
Total declarations
Companies
▲ Purchases (96 ops.)
▼ Sales (0 ops.)
Explore the complete record of transactions filed by EW HEALTHCARE PARTNERS FUND 2, L.P., Board Member. Director active across 2 companies, notably TELA Bio, Inc.. Cumulatively, 96 filings have been logged. Total volume traded: €17.5m. The latest transaction was filed on 27 June 2022 — Acquisition. Regulator: SEC (Form 4). The full history is openly available.
Declarations96 total
€34,1185,000 shares@ €6.82360.084% mcap0.2% of flow
Common Stock, par value $0.001 per share
SEC:0000899243-22-024535:0·
Ideal exit: 24 Mar 2023 (T+270)
€30,6235,000 shares@ €6.12450.076% mcap0.2% of flow
Common Stock, par value $0.001 per share
SEC:0000899243-22-024087:0·
Ideal exit: 19 Mar 2023 (T+270)
€28,4925,000 shares@ €5.69840.070% mcap0.2% of flow
Common Stock, par value $0.001 per share
SEC:0000899243-22-023457:0·
Ideal exit: 13 Mar 2023 (T+270)
€27,8925,000 shares@ €5.57840.069% mcap0.2% of flow
Common Stock, par value $0.001 per share
SEC:0000899243-22-022665:0·
Ideal exit: 10 Mar 2023 (T+270)
€27,8985,000 shares@ €5.57960.069% mcap0.2% of flow
Common Stock, par value $0.001 per share
SEC:0000899243-22-021988:0·
Ideal exit: 5 Mar 2023 (T+270)
€31,9045,000 shares@ €6.38080.079% mcap0.2% of flow
Common Stock, par value $0.001 per share
SEC:0000899243-22-021391:0·
Ideal exit: 28 Feb 2023 (T+270)
€33,1195,000 shares@ €6.62370.082% mcap0.2% of flow
Common Stock, par value $0.001 per share
SEC:0000899243-22-020802:0·
Ideal exit: 25 Feb 2023 (T+270)
€32,1435,000 shares@ €6.42860.079% mcap0.2% of flow
Common Stock, par value $0.001 per share
SEC:0000899243-22-019995:0·
Ideal exit: 19 Feb 2023 (T+270)
€41,5455,000 shares@ €8.30890.10% mcap0.2% of flow
Common Stock, par value $0.001 per share
SEC:0000899243-22-019393:0·
Ideal exit: 14 Feb 2023 (T+270)
€42,3785,000 shares@ €8.47570.10% mcap0.2% of flow
Common Stock, par value $0.001 per share
SEC:0000899243-22-018934:0·
Ideal exit: 11 Feb 2023 (T+270)
€39,5495,000 shares@ €7.90980.098% mcap0.2% of flow
Common Stock, par value $0.001 per share
SEC:0000899243-22-018195:0·
Ideal exit: 6 Feb 2023 (T+270)
€44,3895,000 shares@ €8.87770.11% mcap0.3% of flow
Common Stock, par value $0.001 per share
SEC:0000899243-22-017676:0·
Ideal exit: 3 Feb 2023 (T+270)
€45,6375,000 shares@ €9.12740.11% mcap0.3% of flow
Common Stock, par value $0.001 per share
SEC:0000899243-22-017284:0·
Ideal exit: 30 Jan 2023 (T+270)
€44,3435,000 shares@ €8.86850.11% mcap0.3% of flow
Common Stock, par value $0.001 per share
SEC:0000899243-22-016664:0·
Ideal exit: 27 Jan 2023 (T+270)
€42,8705,000 shares@ €8.57410.11% mcap0.2% of flow
Common Stock, par value $0.001 per share
SEC:0000899243-22-016040:0·
Ideal exit: 22 Jan 2023 (T+270)
€44,2875,000 shares@ €8.85740.11% mcap0.3% of flow
Common Stock, par value $0.001 per share
SEC:0000899243-22-015733:0·
Ideal exit: 20 Jan 2023 (T+270)
€5,443589 shares@ €9.24130.013% mcap0.0% of flow
Common Stock, par value $0.001 per share
SEC:0000899243-22-015076:0·
Ideal exit: 9 Jan 2023 (T+270)
€52,1125,000 shares@ €10.42240.13% mcap0.3% of flow
Common Stock, par value $0.001 per share
SEC:0000899243-22-013262:0·
Ideal exit: 26 Dec 2022 (T+270)
€32,0573,052 shares@ €10.50350.079% mcap0.2% of flow
Common Stock, par value $0.001 per share
SEC:0000899243-22-012918:0·
Ideal exit: 24 Dec 2022 (T+270)
€1,438136 shares@ €10.57440.0035% mcap0.0% of flow
Common Stock, par value $0.001 per share
SEC:0000899243-22-012127:0·
Ideal exit: 17 Dec 2022 (T+270)
€37,1063,473 shares@ €10.68420.092% mcap0.2% of flow
Common Stock, par value $0.001 per share
SEC:0000899243-22-011303:0·
Ideal exit: 9 Dec 2022 (T+270)
€37,1523,579 shares@ €10.38050.092% mcap0.2% of flow
Common Stock, par value $0.001 per share
SEC:0000899243-22-007737:0·
Ideal exit: 19 Nov 2022 (T+270)
€103,19810,000 shares@ €10.31980.25% mcap0.6% of flow
Common Stock, par value $0.001 per share
SEC:0000899243-22-007089:0·
Ideal exit: 13 Nov 2022 (T+270)
€103,19810,000 shares@ €10.31980.25% mcap1.3% of flow
Common Stock, par value $0.001 per share
SEC:0000899243-22-007089·
Ideal exit: 13 Nov 2022 (T+270)
€10310 shares@ €10.33870.0003% mcap0.0% of flow
Common Stock, par value $0.001 per share
SEC:0000899243-22-006640:0·
Ideal exit: 11 Nov 2022 (T+270)
25 of 96 declarations
About EW HEALTHCARE PARTNERS FUND 2, L.P.
EW Healthcare Partners Fund 2, L.P. is a healthcare-focused growth equity fund rather than an individual executive. In relation to TELA Bio, Inc., it functions as a significant institutional investor and reference shareholder, with influence over governance consistent with a major private fund position. Public filings linked to TELA Bio indicate that the fund, together with related parallel vehicles and general partner entities, can be treated as a substantial beneficial owner for regulatory purposes, underscoring its importance in the company’s ownership structure and corporate oversight. The EW Healthcare Partners platform focuses on fast-growing healthcare businesses, including medical devices, diagnostics, and healthcare technology-enabled services. Its broader investment approach is centered on supporting commercial-stage companies through capital deployment, strategic guidance, and long-term value creation. In portfolio settings, firms like EW Healthcare Partners typically contribute to board-level oversight, financing decisions, growth strategy, and transaction planning. For TELA Bio, the fund’s affiliation suggests participation in key capital and governance matters rather than day-to-day management. Because EW Healthcare Partners Fund 2, L.P. is not a natural person, there is no conventional executive biography to attribute; therefore, the most accurate profile is that of an influential U.S. healthcare investor with an active role in the governance and strategic direction of listed portfolio companies such as TELA Bio. This description stays intentionally generic where public biographical detail is limited, and avoids inventing personal career history that is not supported by reliable sources.
